WHO Recommends Against GLP-1s For Young Kids—Amid Wegovy Trial For 6 Year Olds
Despite a nearly 600% surge in adolescent GLP-1 prescriptions, the WHO says they may pose critical safety risks to growing bodies.
Read original article on Forbes - Business →Related news
-
Trump says Russia to supply diesel to US and global markets
-
SentinelOne CFO Sonalee Parekh sells $413,291 in stock
-
FDA approves Hovilpri for refractory HSV in immunocompromised adults
-
Exclusive-Sequoia-backed chip startup Nuvacore raising funds at about a $2.5 billion valuation, sources say
-
Character.AI chatbots encouraged users to cut and starve themselves, Kentucky alleges
-
Super Micro contractor pleads guilty in scheme to divert AI servers with Nvidia chips to China
-
Lockheed unveils next-gen Patriot interceptor to defend against hypersonic threats
-
Clean Air Metals closes C$150,000 private placement